Promotional material

Vaccine update: issue 364, October 2025

Published 24 October 2025

Applies to England

Find Public Health Resources web service is live!

This service is an updated version of Health Publications, please create an account with this service, which works in the same way.

The beta of the Find Public Health Resources service went live on 20 August and was rolled out to all 14,000 users. The new service is designed to meet UK government accessibility requirements and to simplify how health teams find, download and order vaccination information and promotional materials.

Explore Find Public Health Resources

Background and accessibility

The old Health publications website was launched in 2019 and worked well to supply vaccination resources; including all the vast quantities delivered to mass vaccination centres during the pandemic. However, it did not comply with the more recent the Web Content Accessibility Guidelines (WCAG), which public sector organisations in the UK must meet. The new site conforms to the guidelines and follows the POUR principals: content is ‘Perceivable, Operable, Understandable and Robust’. This is important to reduce structural inequalities online.

Find Public Health Resources is the home of the national vaccination programme consent publications. All providers of vaccination must use this service to order consent publications including the leaflets and record cards to match the vaccine stocks that they order through ImmForm. Promotional materials such as posters, stickers and digital resources such as videos and assets for use in patient contact (postcards, email banners and more) play an essential role in the consent process and familiarising the public with the vaccination programmes that they are eligible for and the diseases that these programmes protect against.

Improve health outcomes through vaccines and reduce the impact and burden of infectious diseases and antimicrobial resistance – this is a central aim of the Immunisation and vaccine preventable disease division of UKHSA. Recognising the modern public health digital ecology, positioning a trusted accessible website for all vaccine related information is at the forefront of emergency preparedness and support for the national vaccination programmes which seek to reduce the burden of and eliminate vaccine preventable disease.

The types of resources available to view, download, or order as printed copies include:

• leaflets
• posters
• record cards
• bulletins
• consent forms
• cold chain fridge magnets
• GIFs
• pull-up banner artwork
• slide sets
• stickers
• videos

The service is free of charge to all users. All stakeholders, NHS or DHSC staff can order without limits and members of the public are restricted to 5 of any item.

Demonstrating our commitment to the accessibility of public health information about risk and the benefits of vaccination is critical. Enabling health professionals to have all the resources they need to implement the vaccination programmes in the most equitable way is our initial aim and we hope that all stakeholders and providers will promote and use this service to its fullest to maximise uptake in their communities.

Dr Mary Ramsay, Director of public health programmes, UKHSA

Who should use the service

All vaccination providers and programme partners.

NHS and DHSC staff (no ordering limits).

Members of the public (restricted to 5 of any item).

Organisations and venues that promote vaccination:

• hospital clinics
• A&E
• GP practices
• maternity services
• schools
• colleges
• childcare
• social care
• libraries
• job centres
• prisons
• detention centres
• armed forces
• ports and airports
• charities and welfare organisations

The service should also be used by anyone who wants to promote vaccination, vaccine preventable disease awareness and the importance of routine vaccination in their internal spaces, offline and online in their communications, on websites and in closed community groups. We encourage the widest promotion of the service and hope that every effort will be made to ensure routine vaccination is actively and positively promoted to their audiences all year round

Why use paper leaflets

We encourage using the online links, HTML versions in texts, emails and by sharing links in appointments. Many of our leaflets and posters use QR codes for example which show the leaflet or further reading. We know that this works very well for many people and giving the information in advance of the appointment, in the correct format for the user is often key to the uptake of the appointment and vaccination.

Digital services work well for those people with the equipment, data, signal in their location and income to pay for the service and digital literacy. We have up to 16.5 million people in the UK who are experiencing digital poverty, do not read to an age of 7 years in English, or cannot access the online resources. This is why we recommend a mixed approach of digital communication and having a stock of the leaflets ready to hand to eligible patients at their appointment. Consent to vaccination is a process and is required and offering the national programme leaflets is recommended in each programme PGD and healthcare practitioner guidance documentation.

Paper leaflets:

• ensure equity of access at appointments
• support the consent process recommended in programme PGDs and practitioner guidance
• act as physical reminders that encourage uptake. Leaflets and posters are produced in accessible formats and translated into up to 35 community languages

Best practice

Making time to order, display posters and make the consent publications available along with using the record cards and stickers where applicable is best practice. Nominating a team member to place these orders and replace old stock where leaflets are required is a very effective contribution to improving uptake in your setting. Signing up to receive the Vaccine Update newsletter each month will keep users within the health family up to date with new publications, as well as vaccine supply information and programme changes.

Environmental sustainability

All stock can be safely recycled and is produced on sustainable FSC registered paper with vegetable based dyes. The environmental impact of cases of infectious disease is significantly greater than the paper resources, and the cost of replacing old stock is built in to the commissioning model for their procurement. Each year we plant large quantities of trees for the next generation of sustainable wood pulp based paper. So you can use them, recycle and replace them with confidence knowing that the environmental impact has been carefully managed.

Do I have to pay for this service or delivery?

No, the service is completely free to the user. You do not need an account to view or download free resources. However, you’ll need to sign in to place an order. Please promote Find Public Health Resources to regional communications teams, health professionals, charities and community partners and use the service to support routine vaccination programmes and public awareness activities.

Visit Find Public Health Resources.

If you have questions or feedback about the service, please email publichealthresources@ukhsa.gov.uk

Friends, Families and Traveller’s resources

Friends, Families and Travellers, in partnership with UKHSA and Roma Support Group, have produced a series of short animations with key information on vaccinations. These resources focus on childhood and maternal vaccination as well as measles and whooping cough.

You can find the resources on YouTube using the following links:

• English playlist
• Polish playlist
• Romanian playlist
• Slovak Romanes playlist

You can also find these resources on the Friends Families and Traveller’s website.

If you would like more information about the project and our co-production project, the methodology report is available to read.

COVID-19 Resources

Current vaccines provide good protection against severe disease and hospitalisation. UKHSA surveillance data relating to last autumn’s programme shows that those who received a vaccine were around 43% less likely to be admitted to hospital with COVID-19 from 2 weeks following vaccination, compared to those who remained unvaccinated.

Vaccination continues to help protect against severe illness, hospitalisations and deaths arising from COVID-19. Last winter, between November, December and January around 13,000 people were admitted to hospital with the virus.

The Joint Committee on Vaccination and Immunisation (JCVI) has updated its advice for the autumn 2025 COVID-19 vaccination programme, which has been accepted by ministers. The focus of the programme is shifting towards targeted vaccination of those at highest risk of serious disease.

For autumn 2025, COVID-19 vaccination will be offered to:

• adults aged 75 years and over
• residents in care homes for older adults
• individuals who are immunosuppressed aged 6 months and over

This represents a change from the autumn 2024 programme, which also included adults aged 65 to 74 and all those aged 6 months and over in a clinical risk group.

The eligibility is the same across the 4 nations of the UK (England, Scotland, Wales and Northern Ireland).

The vaccine should usually be offered no earlier than around 6 months after the last vaccine dose. If you are eligible, you can get protection from an autumn COVID-19 vaccination even if you have not taken up a COVID-19 vaccine offer in the past.

Eligibility for the immunosuppressed

We understand that having a weakened immune system (immunosuppression) is a lot less straight forward than the other criteria. Looking online can cause even more confusion, as people might see themselves (and be considered by others) as immunosuppressed but might not fit the immunosuppression criteria for vaccination.

Eligibility is outlined in Chapter 14a of the Green Book some of the groups are listed here:

• organ, bone marrow or stem cell transplant patients
• those being treated with systemic steroids for more than a month
• those living with HIV
• those receiving immunosuppressive or immunomodulating biological therapy, including children who are about to receive therapy
• those undergoing chemotherapy or radiotherapy
• those requiring long-term treatment for immunosuppression
• hose with a history of haematological malignancy including chronic leukaemia, lymphomas, and leukaemia
• those with genetic disorders affecting the immune system

National protocol for COVID-19 vaccine (5 years and over)

Protocol for the administration of COVID-19 mRNA vaccine to individuals aged 5 years and over in accordance with the national COVID-19 vaccination programme

This is available to view on .GOV.UK and NHS.UK

COVID-19 autumn vaccination leaflet

Paper copies of the English version product code: 13114565EN001 of this leaflet are free to order or download.

Translations of this leaflet are available to order and download in: Albanian, Arabic, Bengali, Bulgarian, Chinese Simplified, Chinese Traditional, Dari, English, Estonian, Farsi, French, Greek, Gujarati, Hindi, Italian, Latvian, Lithuanian, Nepali, Panjabi, Pashto, Polish, Portuguese, Romanian, Romany, Russian, Somali, Spanish, Tagalog, Tigrinya, Turkish, Twi, Ukrainian, Urdu, Yiddish and Yoruba.

Stickers

The ‘I have had my autumn COVID-19 vaccination’ stickers are available to order for free. These stickers are available in sheets of 55.

Vaccine supply

Routine vaccination programme

Changes to the routine childhood vaccination schedule since 1 July 2025

The routine childhood vaccination schedule changed on 1 July 2025. All vaccines required to support the routine childhood vaccination schedule remain available to order by ImmForm.

Providers should note that whilst Menitorix® is no longer offered to children turning one year old from 1 July 2025 onwards, Menitorix® will remain available to order by ImmForm for those children previously eligible for it. Once central supplies of Menitorix® deplete, those previously eligible children should be offered a dose of DTaP/Hib/IPV/HepB vaccine, also available by ImmForm.

See more details of the changes to the routine immunisation schedule.

Meningococcal B (Men B) vaccination for protection against gonorrhoea

Since 1 August 2025, Meningococcal B (Men B) vaccination for protection against gonorrhoea is being offered by specialist sexual health services, primarily for gay, bisexual and other men who have sex with men (GBMSM).

Bexsero® (Men B) vaccine is available for sexual health services in England and Wales to order via ImmForm. High-level ordering controls are in place to reduce the risk of ordering errors only. These are not intended to restrict activity. ImmForm customers in Scotland should refer to their local ordering restrictions.

For customers that also access Bexsero® for the infant immunisation programme, when ordering Bexsero®, orders should be placed for the ImmForm product that is specific to the programme for which the stock is intended. Bexsero® ordered for the infant immunisation protection programme should not be used for the GBMSM gonorrhoea protection programme and vice versa.

Bexsero® vaccine ordered via ImmForm is supplied as a ten-dose pack, containing ten pre-filled syringes of vaccine and one patient information leaflet (PIL). Each 10-dose pack of Bexsero® vaccine ordered via ImmForm is supplied with a pad of 10 additional PILs.

The 10-dose pack of Bexsero® vaccine supplied by ImmForm does not contain needles for administration. Guidance on the choice of needle size can be found in the Green book chapter 4. Needles should be obtained locally.

Please add Bexsero® vaccine to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, order no more than 2 weeks’ worth of stock.

Details about meningococcal B (Men B) vaccination for use against gonorrhoea can be found in the on the guidance leaflet.

Further details about Bexsero® vaccine can be found in the patient information leaflet (PIL).

Contact the helpdesk@immform.org.uk for ordering queries.

Routine mpox vaccination programme

Since summer 2025, a routine mpox vaccination programme is being offered by specialist sexual health services, primarily for gay, bisexual and other men who have sex with men (GBMSM).

Imvanex® (mpox) vaccine is available for Scotland Health Boards, and sexual health services in England and Wales to order via ImmForm. High-level ordering controls are in place to reduce the risk of ordering errors only. These are not intended to restrict activity. ImmForm customers in Scotland should refer to their local ordering restrictions.

Imvanex® vaccine ordered via ImmForm is supplied as a 10-dose pack, containing ten vials (10 x 0.5 ml) of vaccine and one patient information leaflet (PIL). Each 10-dose pack of Imvanex® vaccine ordered via ImmForm is supplied with a pad of 10 additional PILs and a Dear Healthcare Professionals (DHCP) letter explaining the provision of a non-UK licensed pack.

Imvanex® vaccine ordered via ImmForm is delivered to customers on their routine weekly delivery day, in an isothermic shipper with an internal temperature of –20°C. The isothermic shipper is recycled by Movianto who will either retain the shipper at the time of delivery to ImmForm customers or arrange for its collection on a later date. ImmForm customers should therefore not dispose of the isothermic shipper.

Upon receipt on Imvanex® vaccine ordered via ImmForm, customers can continue to store the Imvanex® vaccine at –20°C to retain the –20°C expiry shown on the delivery note and pack. Alternatively, customers can store Imvanex® vaccine at +2 to +8°C, with the vaccine then having an expiry date of 8 weeks from the time when the vaccine was removed from its –20°C storage.

The 10-dose pack of Imvanex® vaccine supplied by ImmForm does not contain needles for administration. Guidance on the choice of needle size can be found in the Green book, chapter 4. Needles should be obtained locally.

To help with planning storage requirements, the dimensions of the 10-dose pack of Imvanex® vaccine are 54 x 38 x 92mm (H x W x D). Please see the Storage, distribution and disposal of vaccines: the green book, chapter 3 for further guidance .

To minimise wastage due to fridge failures, order no more than 2 weeks’ worth of stock.

Details about mpox vaccination can be found at in the programmes letter. Additional programme resources are available at Vaccination against mpox.

Further details about Imvanex® vaccine can be found in the manufacturer’s Summary of product characteristics (SmPC)

Contact the helpdesk@immform.org.uk for ordering queries.

Vaccines for the 2025 to 2026 children’s flu programme supplied by UKHSA

All flu vaccines for the 2025/26 children’s flu programme are available to order by general practice and school-age providers in England via ImmForm.

Community pharmacies who are delivering flu vaccinations to 2 and 3 year olds can access Fluenz® (LAIV) via the Federated Data Platform (FDP) managed by NHS England. Vaccines for this service will not be available to order through ImmForm. UKHSA does not supply any flu vaccines for patients aged 18 years and over.

Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Vaccines and availability

The 2 vaccines that will be available, preliminary indicative ordering dates and the groups that these vaccines should be ordered for are set out in the table below.

Vaccine	Manufacturer	Available to order for
Fluenz® (LAIV)	AstraZeneca	All children from 2 years of age to school year 11 Children in clinical risk groups aged 2 to <18 years [note 1]
Cell Based Trivalent Influenza Vaccine (Surface Antigen, Inactivated) (TIVc)	Seqirus	Children in clinical risk groups aged 6 months to <2 years  All other eligible [note 2] children aged 2 to <18 years for whom LAIV is unsuitable

Note 1: Unless LAIV clinically contraindicated or otherwise unsuitable.

Note 2: Children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to less than 18 years.

Children’s flu vaccine supply for programme delivery innovation

We are aware of increasing activity across England, in particular by primary care networks (PCNs), to deliver the programme to 2 and 3 year olds by innovative models (such as in a nursery setting). If you are planning any such activity, we advise that you contact childfluvaccine@ukhsa.gov.uk to discuss your plans. This will enable us to support you with any additional supply requirements or any other supply-related advice

LAIV ordering information for general practice

Ordering controls will be in place for general practices, to enable UKHSA to balance supply with demand. These controls will work by allocating an amount of LAIV based on the umber of registered eligible patients and will be tailored to each practice.

• each GP practice will initially be allocated sufficient LAIV to vaccinate at least 45% of its eligible patients (all 2 and 3 year olds, plus children in clinical risk groups from age 4 to less than 18 years) when ordering commences
• increases to these allocations will be made in response to demand and vaccine availability
• requests for extra vaccine will be considered on a case-by-case basis throughout the ordering period – requests for additional vaccine should be sent to the helpdesk (helpdesk@immform.org.uk) and should be sent in good time before your order cut-off
• out-of-schedule deliveries will be by exception only

This vaccine has a short shelf life. Try to hold no more than 2 weeks’ stock at a time and re-order regularly to reduce local wastage through expiry before use.

Multi-branch practices and LAIV allocations

GP practices or groups that operate over multiple sites but are part of the same organisation will have a joint allocation (as in previous years), even where each site has a unique ImmForm account. This means that it is possible for one site to potentially order all of the available vaccine for the group, unless there is local agreement on how the allocated volume is shared. UKHSA recommend that this agreement is in place before ordering opens to reduce the risk of supply interruption. The information above allows practices to estimate the amount of vaccine they will be initially allocated, and how it should be split between all sites.

LAIV ordering information for school-age providers

LAIV ordering information for school-age providers School providers are able to place 2 orders and receive 2 deliveries of LAIV per week, to assist in the management of vaccine volumes required across limited storage space at delivery points.

This operates on a 48-hour delivery schedule requiring the order to be placed before the 11.55am cut-off 2 working days before the required delivery day. The table below illustrates the respective delivery days versus ordering day.

Order day (before 11.55am cut off)	Delivery day
Monday	Wednesday
Tuesday	Thursday
Wednesday	Friday
Thursday	Monday
Friday	Tuesday

Customers must ensure that the point of delivery will be open and staffed between 9am and 5pm on the delivery day when placing orders.

Please note that this does not affect the routine ordering and delivery schedule of any other vaccines (including inactivated flu vaccines) ordered from ImmForm and is applicable to Fluenz® (LAIV) only.

A default weekly ordering cap of 450 packs (4,500 doses) per week is in place for school provider accounts. Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example where a provider covers a large area using a single account), a higher weekly cap should be requested via the UKHSA Flu Vaccine Operations team by emailing childfluvaccine@ukhsa.gov.uk and providing your ImmForm account number or Org code.

For one-off larger orders during the ordering period, requests should be made via helpdesk@immform.org.uk.

Inactivated flu vaccine ordering

The Cell Based Trivalent Influenza Vaccine (Surface Antigen, Inactivated) (TIVc) will be available to order, in a single dose pack, for:

• children in clinical risk groups aged from 6 months to less than 2 years old
• children aged from 2 to less than 18 years old in clinical risk groups for whom LAIV is clinically contraindicated or otherwise unsuitable
• healthy children from 2 years old to those in school year 11, for whom LAIV is unsuitable (for example, due to objection to LAIV on the grounds of its porcine gelatine content)

Order controls will also be in place for this vaccine as follows:

• for GPs, there will be an initial cap of 10 doses/packs per week
• for school-age providers, there will be a cap of 450 doses/packs per week

Influenza vaccines for the 2025 to 2026 season

Information on all influenza vaccines that will be marketed in the UK for the 2025 to 2026 season are available on the flu vaccination page on GOV.UK.

Impact of changes to opening hours on routine vaccine deliveries

Consider temporary changes to opening times when placing ImmForm orders. Orders should only be placed for days when your site is open and capable of receiving them. If you are aware of a scheduled site closure, refrain from placing an order for that date. In case of a one-off closure, consider rescheduling your order for the week before or after. This approach will contribute to improved overall efficiencies and enhance delivery performance for the benefit of all customers.

It is not possible to accommodate one-off changes to delivery days. Customers should report long-term changes to the days and times when they can accept deliveries, such as routine training days and closures, by contacting Movianto UK Customer Care on MoviantoUK.NHSCC@movianto.com and 01234 587207. This should not be used to report short-term changes due to absence or holidays.

Depletion of Vaxelis® for DTaP/IPV/Hib/HepB vaccination

Vaxelis® vaccine is no longer supplied by UKHSA via ImmForm. Infanrix hexa is now the only DTaP/IPV/Hib/HepB vaccine available to order by ImmForm. Orders for Infanrix hexa® remain unrestricted.

Providers should not order more than 2 weeks’ worth of stock to minimise wastage due to fridge failures. For assistance, please contact the ImmForm Helpdesk at helpdesk@immform.org.uk

MMR vaccine ordering

M-M-RvaxPro vaccine should be ordered for all MMR vaccinations, unless a patient requires a porcine gelatine-free MMR vaccine. ImmForm customers in England and Wales may order M-M-RvaxPro vaccine without restriction.

In addition, ImmForm customers in England and Wales may order up to 10 porcine gelatine-free Priorix vaccines per account per week.

ImmForm customers in Scotland should refer to their local ordering restrictions.

Both MMR vaccines may only be ordered for outbreak purposes when this is part of a national catch-up campaign

Non-routine vaccine supply

Hepatitis A vaccine

Adult

GSK: supply of Havrix Adult PFS singles and packs of 10 are currently available.

Sanofi : Avaxim PFS singles are currently available. Avaxim packs of 10 are currently available.

MSD: VAQTA Adult is available.

Paediatric

GSK: supply of Havrix Paediatric singles and packs of 10 are currently available.

MSD: VAQTA Paediatric is available.

Sanofi Pasteur: Avaxim Junior singles are currently available.

Hepatitis B vaccine

Adult

GSK: Engerix B PFS singles and packs of 10 are currently available.

GSK: supply of Fendrix is currently available.

MSD: HBVAXPRO 10μg is available.

MSD: HBVAXPRO 40μg is available.

Valneva: PreHevbri is no longer marketed in the UK.

Paediatric

GSK: supplies of Engerix B Paediatric singles are currently available.

MSD: HBVAXPRO 5μg is available.

Combined hepatitis A and B vaccine

GSK: Twinrix Adult singles and packs of 10 are available.

GSK: Twinrix Paediatric is currently available.

GSK: Ambirix is available.

Combined hepatitis A and typhoid vaccine

Sanofi: Viatim is now a discontinued product and no longer available for sale.

Typhoid vaccine

Bavarian Nordic: Vivotif is available.

Sanofi: Typhim singles and packs of 10 are available.

Rabies vaccine

Bavarian Nordic: Rabipur is currently available.

Sanofi: Verorab is available to order with some restrictions – this product is capped for wholesalers at 250 doses per month

Pneumococcal polysaccharide vaccine (PPV)

MSD: Private supply of Pneumovax 23 (PPV23) PFS is to be discontinued from October 2025

Pneumococcal polysaccharide conjugate vaccine (PCV)

Pfizer: Prevenar 13 is currently available.

Pfizer: Prevenar 20 is currently available.

MSD: Vaxneuvance is currently available.

Varicella zoster vaccine

GSK: VARILRIX is currently available.

MSD: VARIVAX is available.

MSD: ZOSTAVAX is a discontinued product.

Diphtheria, tetanus and poliomyelitis (inactivated) vaccine

Sanofi: Revaxis is available.

Diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated) vaccine

GSK: supply of Boostrix-IPV is currently available.

Sanofi: Repevax is currently available.

MMR vaccine

MSD: MMR VaxPro is currently available.

GSK: Priorix is currently available.

Meningitis ACWY vaccine

GSK: Menveo is currently available.

Pfizer: Nimenrix is currently available.

Sanofi: MenQuadfi is available.

Yellow fever vaccine

Sanofi: Stamaril is available to order without restrictions

Human papillomavirus vaccine

MSD: GARDASIL has been discontinued.

MSD: Gardasil 9 is currently available.

GSK: Cervarix has been discontinued.

Cholera vaccine

Bavarian Nordic: Vaxchora is available.

Valneva: Dukoral is available.

Japanese encephalytis vaccine

Valneva: Ixiaro is available.

Meningococcal group B vaccine

GSK: Bexsero is currently available.

Diphtheria, tetanus, pertussis, Hib vaccine and poliomyelitis

GSK: Infanrix IPV+Hib is currently available.

Hib + meningococcal group C combined vaccine

GSK: Menitorix is currently available.

Live attenuated rotavirus vaccine

GSK: Rotarix is currently available.

Herpes zoster vaccine

GSK: Shingrix is currently available.

Diphtheria, tetanus and pertussis

Sanofi: Adacel is currently available

Dengue tetravalent vaccine

Takeda: Qdenga is currently available.

Respiratory syncytial virus vaccine

Pfizer: Abrysvo is currently available.

GSK: Arevxy is currently available.

Chikungunya vaccine

Valneva: IXCHIQ®▼ is available. Please read important MHRA Drug Safety update on IXCHIQ® powder and solvent for solution for injection Chikungunya vaccine (live).

Bavarian Nordic: Vimkunya®▼ is available